Treatment of ventricular arrhythmias with oral sotalol in four horses.

Overview

• This study reports on the use of oral sotalol to treat sustained ventricular arrhythmias (VAs) in four horses.
• The treatment successfully normalized heart rhythm without adverse effects, suggesting sotalol as a potential option when other treatments are limited.

Background

• Ventricular arrhythmias (VAs) are abnormal heart rhythms originating from the ventricles that can pose a serious health risk in horses.
• Sustained VAs can cause hemodynamic or electrical instability, requiring prompt medical treatment to prevent complications.
• Traditional antiarrhythmic treatments in horses typically include medications like lidocaine and magnesium administered intravenously or through other parenteral routes.
• Other antiarrhythmic drugs exist but their use is often limited due to concerns about side effects, high costs, difficulties in administration, and lack of easy access.

Current Usage of Sotalol

• Sotalol is a beta-blocker with antiarrhythmic properties, primarily used in horses to prevent recurrent atrial fibrillation or to suppress ectopy from both supraventricular and ventricular origins.
• There are anecdotal reports of oral sotalol administration for VA treatment but no systematic study previously documented.

The Case Series

• This research article presents a case series involving four horses with sustained ventricular arrhythmias treated with oral sotalol.
• The treatment resulted in successful conversion of the arrhythmias to either a predominantly normal sinus rhythm or a baseline pre-existing atrial fibrillation rhythm.
• No adverse effects were reported in these cases, indicating good tolerability of oral sotalol in these horses.

Implications and Recommendations

• Oral sotalol appears to be a viable treatment option for selected horses with hemodynamically stable ventricular arrhythmias.
• It may be particularly useful in situations where standard treatments like lidocaine and magnesium cannot be used due to unavailability, ineffectiveness, or financial constraints.
• This highlights oral sotalol as a potentially important alternative antiarrhythmic drug in equine medicine.
• Further studies are needed to establish dosing guidelines, safety profile, and long-term efficacy of sotalol for treating ventricular arrhythmias in horses.